Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Partnership for Research on Ebola Vaccinations (PREVAC)
2017-001798-18Phase 2
- Sponsor
- Inserm
- Start
- May 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of rVSVN4CT1-EBOVGP1 in Ebola virus disease (EVD), sponsored by Inserm. Primary endpoint: GP-EBOV antibody response at 12 months.
02
Drugs
rVSVN4CT1-EBOVGP1
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on 2017-001798-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001798-18.